Cholinergic anti-inflammatory pathway

The Cholinergic Anti-Inflammatory Pathway: What You Can Measure

The cholinergic anti-inflammatory pathway is acetylcholine switching off TNF release from macrophages through the alpha-7 receptor, a finding mapped in mice rather than people. What a practice can document is autonomic, vascular, cardiometabolic, body-composition and cognitive function in the same patient; motility and disease activity belong to gastroenterology.

Patients bring this pathway to clinic as a question about nicotine. The receptor biology is real, the delivery question is unanswered, and the measurable part of it sits outside the colon.

The cholinergic anti-inflammatory pathway usually reaches a clinic as a question, not a prescription. A patient whose distal ulcerative colitis surfaced eleven months after she stopped smoking asks whether she should start again, and nobody has answered her, because the honest sentence sounds like an endorsement of tobacco. The answer is no. The useful work is separating three claims that get merged: an immune receptor, a motor receptor and a delivery route. The video above closes The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes.

The cholinergic anti-inflammatory pathway: two receptors, two arguments

The immune arm is better mapped and it is not human. Acetylcholine cannot switch off macrophage TNF release without the alpha-7 subunit, and in mice bred without it the vagal suppression of TNF disappears entirely. In an inflamed gut wall it sits on monocytes and macrophages rather than neurons. Rodent work throughout.

Fast transmission between enteric neurons runs on a different assembly: blocking the alpha-3-beta-4 type drops evoked responses, while an alpha-7 antagonist had no effect at any developmental age. Motor and immune actions are separable, and evidence that looks contradictory stops conflicting once sorted that way.

The human anchor is thinner and more interesting than either. Surgical colon answered a nicotinic stimulus with action potentials in 51 neurons, drawn from 20 myenteric ganglia in 19 patients and bursting 2 to 23 times near 5.3 Hz, while only about 8% of the myenteric neurons responded at all, which the authors call low. The same tissue bank puts myenteric density near 84 neurons per square millimeter in sigmoid and rectum against 38 in the ascending colon: twice the wiring, where distal disease sits.

What the trials support, and where the ceiling is

Pooled data put transdermal nicotine ahead of placebo for inducing remission. Then the ceiling, from the same review: against prednisone or mesalamine, no advantage. A broader meta-analysis found no efficacy, with a relative risk of 1.40 whose interval crosses one, and harm at 1.95. Harm replicated where benefit did not.

The randomized rectal route used a 6 mg liquid preparation and failed, with remission at 27% against 33% on placebo and the authors calling the enemas well tolerated but not efficacious. Tolerability was the one problem local delivery solved: one of 104 patients stopped for harm.

The position, stated exactly. The formulation is the claim: a small dose held against the distal colonic mucosa, not a whole patient dosed through the skin. No published trial of a nicotine suppository exists, in any indication, anywhere; the group that built such formulations assayed release in a dish and stopped there. A failed patch and a failed liquid enema are not evidence against a preparation nobody has administered, and an untested preparation is not a proven one. None of this is a reason for a patient to use nicotine in any form.

On motility, keep two claims apart. The evacuation claim is supported in humans: transient high-amplitude propagated contractions and faster colonic transit followed a high dose in healthy subjects, mass peristalsis recorded rather than inferred from a receptor map. The migrating motor complex claim is not, and no controlled human trial of nicotine for a stalled motor complex exists. Motility studies are not in this test library; they belong to gastroenterology, with endoscopy and stool markers.

Three measurement failures worth carrying into your own practice

First, the tissue was never sampled. No study has measured nicotine concentration in rectal mucosal tissue, so the local-delivery premise is inferred from serum. A mechanism assayed one compartment away from where it supposedly acts is a hypothesis, not a demonstration.

Second, the level did not predict the patient. In the liquid enema pilot, 4 of 10 patients had adverse events while serum nicotine was low or undetectable. Managing by concentration would have missed all of them.

Third, a dosing signal sat unused in an adverse-event table. In the carbomer enema study the subjects who reported side effects were all female lifelong nonsmokers of low body weight, and inflamed bowel absorbed the dose more slowly, peaking at 60 minutes against 45. Exposure scales to the compartment holding it, which body weight alone does not describe.

Who to test, what changes, and how the baseline is captured

Measura [Cardiometabolic and Autonomic Health Analysis] measures cardiometabolic and autonomic function. It does not treat, and it does not grade disease activity in a bowel. What it documents is the physiology a cholinergic drug discussion assumes and nobody records.

• Autonomic nervous system testing and cardiac autonomic reflex tests record how heart rate and blood pressure answer standardized challenges, which makes a later change interpretable instead of anecdotal.
• Heart rate variability quantifies beat-to-beat variation. It measures tone, not a receptor or a cytokine, and should never be presented as either.
• Arterial stiffness and endothelial function measures vessel behavior directly, where older trials reached for a circulating marker of endothelial damage.
• Laboratory panels carry the acute-phase and metabolic markers you select.
• Bioimpedance body composition separates lean from fat mass, the compartment that adverse-event table pointed at when the lightest patients fared worst.

What a finding changes is modest and concrete. An autonomic or vascular abnormality documented before a cessation program, or before any drug with cholinergic or sympathomimetic effects, becomes the comparator for everything after it. Without one, a later symptom has nothing to be measured against.

Workflow decides whether any of this happens. Standing orders capture a baseline without a fresh decision at every visit, the annual wellness visit is the natural slot, and getting results into the record turns a study into documentation that supports MIPS and HEDIS quality reporting. In older patients the same visit documents cognitive assessment and fall prevention, and selection criteria keep testing pointed where a result changes something. The patient-facing version is what your patients are reading.

The strongest case against all of it

The strongest argument is not danger. It is that the molecule has had its chance: four preparations, two groups, three decades, harm replicating and benefit not. The 6 mg liquid vehicle is done, and so is the patch as monotherapy.

What does not follow is that one dose in one vehicle settles a route, particularly when that trial never recorded how long its own enemas stayed in, and when 3 of 10 patients in an earlier pilot quit inside a week, unable to retain the liquid. One caution runs against my own reading: some blood leaving the lower rectum skips the liver altogether, so a preparation sitting low could put more drug per milligram into the rest of the patient, not less. Unmeasured either way.

The honest mechanistic route runs away from the molecule. Rats with postoperative ileus were given a serotonin receptor agonist, which pushed cholinergic neurons to release more acetylcholine and quieted the macrophages of the muscle layer; ganglionic blockade, or an alpha-7 antagonist, abolished it, and motility and white-cell infiltration improved together. Rodent data, and the effective drug was serotonergic. No nicotinic agonist has ever been developed as a gut prokinetic.

So the instruction is unchanged. Counsel against resuming smoking, document the interval from quit date to diagnosis, offer no nicotine, and do not let the awkwardness of the question substitute for an answer: a patient who carries it alone for two years has been managed by silence. Rescue is not repair. Every study named here sits with its limits in the companion deep dive, and specialty applications covers where this fits by discipline.

Frequently asked questions

References

• Wang, H., Yu, M., Ochani, M., Amella, C. A., Tanovic, M., Susarla, S., Li, J. H., Wang, H., Yang, H., Ulloa, L., Al-Abed, Y., Czura, C. J., & Tracey, K. J. (2003). Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature, 421(6921), 384-388. https://doi.org/10.1038/nature01339
• Elfers, K., Sehnert, A. S., Wagner, A., Zwirner, U., Linge, H., Kulik, U., Poehnert, D., Winny, M., Gundert, B., Aselmann, H., & Mazzuoli-Weber, G. (2024). Functional and structural investigation of myenteric neurons in the human colon. Gastro Hep Advances, 4(1), 100537. https://doi.org/10.1016/j.gastha.2024.08.016
• Foong, J. P. P., Hirst, C. S., Hao, M. M., McKeown, S. J., Boesmans, W., Young, H. M., Bornstein, J. C., & Vanden Berghe, P. (2015). Changes in nicotinic neurotransmission during enteric nervous system development. The Journal of Neuroscience, 35(18), 7106-7115. https://doi.org/10.1523/JNEUROSCI.4175-14.2015
• Tsuchida, Y., Hatao, F., Fujisawa, M., Murata, T., Kaminishi, M., Seto, Y., Hori, M., & Ozaki, H. (2011). Neuronal stimulation with 5-hydroxytryptamine 4 receptor induces anti-inflammatory actions via alpha7nACh receptors on muscularis macrophages associated with postoperative ileus. Gut, 60(5), 638-647. https://doi.org/10.1136/gut.2010.227546
• McGrath, J., McDonald, J. W. D., & Macdonald, J. K. (2004). Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews(4), CD004722. https://doi.org/10.1002/14651858.CD004722.pub2
• Nikfar, S., Ehteshami-Ashar, S., Rahimi, R., & Abdollahi, M. (2010). Systematic review and meta-analysis of the efficacy and tolerability of nicotine preparations in active ulcerative colitis. Clinical Therapeutics, 32(14), 2304-2315. https://doi.org/10.1016/j.clinthera.2011.01.004
• Ingram, J. R., Thomas, G. A. O., Rhodes, J., Green, J. T., Hawkes, N. D., Swift, J. L., Srivastava, E. D., Evans, B. K., Williams, G. T., Newcombe, R. G., Courtney, E., & Pillai, S. (2005). A randomized trial of nicotine enemas for active ulcerative colitis. Clinical Gastroenterology and Hepatology, 3(11), 1107-1114. https://doi.org/10.1016/s1542-3565(05)00849-9
• Coulie, B., Camilleri, M., Bharucha, A. E., Sandborn, W. J., & Burton, D. (2001). Colonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjects. Alimentary Pharmacology & Therapeutics, 15(5), 653-663. https://doi.org/10.1046/j.1365-2036.2001.00959.x
• Sandborn, W. J., Tremaine, W. J., Leighton, J. A., Lawson, G. M., Zins, B. J., Compton, R. F., Mays, D. C., Lipsky, J. J., Batts, K. P., Offord, K. P., Hurt, R. D., & Green, J. (1997). Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: A pilot study. Alimentary Pharmacology & Therapeutics, 11(4), 663-71. https://doi.org/10.1046/j.1365-2036.1997.00208.x
• Green, J. T., Thomas, G. A., Rhodes, J., Evans, B. K., Russell, M. A., Feyerabend, C., Fuller, G. S., Newcombe, R. G., & Sandborn, W. J. (1997). Pharmacokinetics of nicotine carbomer enemas: A new treatment modality for ulcerative colitis. Clinical Pharmacology and Therapeutics, 61(3), 340-8. https://doi.org/10.1016/S0009-9236(97)90167-3

Related reading

• Low Dose Naltrexone Mechanism of Action: Four Links, Each With a Tier
• Autonomic Nervous System Testing

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed September 12, 2026.